Journal article

Differing Effects of Zoledronic Acid on Bone Microarchitecture and Bone Mineral Density in Men Receiving Androgen Deprivation Therapy: A Randomized Controlled Trial

Ada S Cheung, Rudolf Hoermann, Ali Ghasem-Zadeh, Alistair J Tinson, Vivian Ly, Stefan Milevski, Daryl Lim Joon, Jeffrey D Zajac, Ego Seeman, Mathis Grossmann

Journal of Bone and Mineral Research | WILEY | Published : 2020

Abstract

Androgen deprivation therapy (ADT) given to men with prostate cancer causes rapid and severe sex steroid deficiency leading to increased bone remodeling and accelerated bone loss. To examine the effects of a single dose of zoledronic acid on bone microarchitecture we conducted a two year randomised placebo controlled trial in 76 men, mean age [IQR] 67.8 years [63.8;73.9] with non-metastatic prostate cancer commencing adjuvant ADT; 39 were randomised to zoledronic acid and 37 to matching placebo. Bone microarchitecture was measured using high resolution-peripheral quantitative computed tomography (HR-pQCT). Using a mixed model, mean adjusted differences (MAD [95% CI]) between the groups are r..

View full abstract

Grants

Awarded by National Health and Medical Research Council (NHMRC) of Australia Project Grant


Awarded by NHMRC Medical and Dental Postgraduate Research Scholarship


Awarded by NHMRC Early Career Fellowship


Awarded by NHMRC Career Development Fellowship


Funding Acknowledgements

The study was funded by a National Health and Medical Research Council (NHMRC) of Australia Project Grant (#1062073). AC was supported by a NHMRC Medical and Dental Postgraduate Research Scholarship (#1017233), NHMRC Early Career Fellowship (#1143333), and an Endocrine Society of Australia Postdoctoral Award. MG was supported by a NHMRC Career Development Fellowship (#1024139).